John W. Kozarich - 16 May 2023 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Director
Signature: /s/ Andrew Reardon, Attorney-in-Fact for John W. Kozarich
Issuer symbol: LGND
Transactions as of: 16 May 2023
Net transactions value: -$343,081
Form type: 4
Filing time: 18 May 2023, 17:18:57 UTC
Previous filing: 10 May 2023
Next filing: 13 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Sale	$343,081	-4,444	-10%	$77.20	38,488	16 May 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $77.20 to $77.24. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2	The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein.

Content

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $77.20 to $77.24. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

The number reflected in Column 5 reconciles the total number of shares beneficially held following the transactions reported herein.